Guardant Health’s Shield Blood Test Added to Cancer Screening Guidelines for 50M Unscreened
GH•Guardant Health’s FDA-approved Shield blood test is now recommended in updated colorectal cancer screening guidelines for average-risk adults 45+, offering a new choice to over 50 million unscreened Americans. Real-world data from 200,000 patients shows over 90% adherence; the ECLIPSE study reported 100% sensitivity for stage II+ cancers.
1. Guideline Update and Recommendation
The American Cancer Society’s updated colorectal cancer screening guidelines now include Guardant Health’s FDA-approved Shield blood test as a recommended option for average-risk adults age 45 and older who decline or do not complete stool-based or visual screening methods.
2. Real-World Evidence and Study Results
In a real-world cohort of approximately 200,000 patients, Shield achieved over 90% screening adherence; the pivotal ECLIPSE study demonstrated 100% sensitivity in detecting stage II and above colorectal cancers, underscoring its effectiveness as a blood-based screening modality.
3. Market Implications and Patient Impact
By adding a non-invasive blood test option, the guidelines aim to reach more than 50 million unscreened Americans, potentially increasing overall screening rates, driving higher test volumes for Guardant Health and improving early cancer detection across diverse patient groups.
